Back

Beta-blockers after myocardial infarction: are we treating without evidence? a systematic review and meta-analysis

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: New perspectives in cardiology (1) - Aggressive ways of saving patients Pharmacotherapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Rafael Alessandro Ferreira Gomes

Real Hospital Portugues de Beneficencia, Recife (Brazil)

9 More presentations in this session

Presentation thumbnail
Discussant - Aggressive ways of saving patients
Presentation thumbnail
Prognostic significance of histological diagnosis in acute myocarditis with fulminant presentation
Doctor Y. Takei (Tokyo, JP)
Abstract Slides Video
Presentation thumbnail
Novel semi-invasive pressure-volume loop analysis for hemodynamic assessment and risk stratification across SCAI stages in cardiogenic shock
Doctor J. Ortega-Hernandez (Ciudad de Mexico, MX)
Abstract Slides Video
Presentation thumbnail
Impact of the combined use of VA-ECMO and impella (ECPELLA) on short-term mortality in cardiogenic shock patients receiving VA-ECMO: a propensity score-matched analysis
Doctor T. Inamori (Kumamoto, JP)
Abstract Slides
Presentation thumbnail
Efficacy and safety of oral acetazolamide in patients with decompensated heart failure: hospital phase of open-label prospective randomized multicenter study ORION-A
Professor I. Sabirov (Bishkek, KG)
Abstract Slides Video

Access the full session

Session thumbnail
New perspectives in cardiology (1) - Aggressive ways of saving patients

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Betablockers post-acute myocardial infarction
thumbnail
Congress Session
HOT LINE 3
thumbnail
Congress Presentation
REBOOT/BETAMI/DANBLOCK/CAPITAL-RCT: Beta-Blockers after MI with Mildly Reduced EF (an IPD meta-analysis)

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources